| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
DL-Homocysteinethiolactone HCl does not have a well-defined primary drug target but is known to interact with various plasma proteins and enzymes involved in homocysteine metabolism. It can bind to and induce conformational changes in plasma proteins, affecting coagulation and oxidative stress pathways.
|
|---|---|
| ln Vitro |
Barnyard grass and rapeseed root growth are inhibited by DL-homocysteine thiolactone hydrochloride, even at low concentrations of 50 μM [1].
In vitro, DL-Homocysteine thiolactone hydrochloride shows growth inhibition toward the roots of Brassica campestris and Echinochloa utilis at concentrations as low as 50 μM. It is a cyclic amino acid derivative that exhibits root-growth inhibitory activity. The compound can also affect cellular redox balance and induce oxidative stress. |
| ln Vivo |
In vivo studies have demonstrated that acute administration of DL-Homocysteinethiolactone hydrochloride induces seizures and decreases left ventricular systolic blood pressure and cardiac force. These effects are consistent with its ability to modulate cardiovascular and neurological functions through interaction with homocysteine-sensitive pathways.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for DL-Homocysteinethiolactone HCl typically involve studying its interaction with homocysteine-metabolizing enzymes such as methionine synthase or cystathionine β-synthase. Binding affinity is determined using surface plasmon resonance or isothermal titration calorimetry. The compound's ability to inhibit enzyme activity is measured using spectrophotometric or fluorometric methods that track substrate conversion or cofactor utilization.
|
| Cell Assay |
Cell culture experiments with DL-Homocysteinethiolactone HCl involve treating various cell lines (e.g., endothelial cells, neuronal cells) with concentrations ranging from 10 μM to 1 mM. Cellular effects assessed include viability (MTT assay), oxidative stress markers (ROS detection, glutathione levels), and apoptosis (caspase activation, Annexin V staining). The compound is typically dissolved in culture medium and incubated for 24-72 hours before analysis.
|
| Animal Protocol |
In vivo animal studies typically involve intraperitoneal or intravenous administration of DL-Homocysteinethiolactone HCl to rodents. Acute effects on cardiovascular parameters (blood pressure, heart rate) are monitored using telemetry or catheterization. Seizure activity is assessed by behavioral observation and EEG recording. Dose-response relationships are established to determine the compound's potency in inducing these physiological effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DL-Homocysteinethiolactone HCl are characteristic of small cyclic amino acid derivatives. Following administration, the compound is rapidly distributed throughout the body and can cross the blood-brain barrier. It undergoes hydrolysis to homocysteine, which is then metabolized via transsulfuration or remethylation pathways. The compound has a relatively short half-life, with excretion primarily through renal clearance.
|
| Toxicity/Toxicokinetics |
Toxicological studies indicate that DL-Homocysteinethiolactone HCl can induce oxidative stress and cellular damage at high concentrations. Acute toxicity manifests as seizures, cardiovascular depression, and potential neurotoxicity. Chronic exposure may contribute to hyperhomocysteinemia-related pathologies, including cardiovascular disease and neurological disorders. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
DL-Homocysteinethiolactone HCl is primarily a research tool for studying homocysteine metabolism, oxidative stress, and related pathological conditions. It is used to model hyperhomocysteinemia in cell culture and animal studies. The compound has no approved clinical applications but serves as a valuable reagent for investigating the biochemical and physiological roles of homocysteine in health and disease.
|
| Molecular Formula |
C4H8CLNOS
|
|---|---|
| Molecular Weight |
153.624
|
| Exact Mass |
153.001
|
| CAS # |
6038-19-3
|
| Related CAS # |
L-Homocysteine thiolactone hydrochloride;31828-68-9;DL-Homocysteine thiolactone-d4 hydrochloride;1219805-31-8
|
| PubChem CID |
110753
|
| Appearance |
White to off-white solid powder
|
| Density |
0.862 g/cm3
|
| Boiling Point |
253.8ºC at 760 mmHg
|
| Melting Point |
202 °C (dec.)(lit.)
|
| Flash Point |
107.3ºC
|
| LogP |
1.479
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
93.7
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZSEGSUBKDDEALH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H7NOS.ClH/c5-3-1-2-7-4(3)6;/h3H,1-2,5H2;1H
|
| Chemical Name |
3-aminothiolan-2-one;hydrochloride
|
| Synonyms |
HCTL hydrochloride; D,L-Homocysteine thiolactone hydrochloride; (+-)-Dihydro-3-amino-2(3H)-thiophenone hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~325.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5096 mL | 32.5478 mL | 65.0957 mL | |
| 5 mM | 1.3019 mL | 6.5096 mL | 13.0191 mL | |
| 10 mM | 0.6510 mL | 3.2548 mL | 6.5096 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
